Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
article/pii/S0140673624014983 [Additional references continue covering all cited sources from the searches conducted] [1] Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial ScienceDirect science/article/pii/S0140673624014983 [2] The SELECT trial of semaglutide in patients with overweight or obesity without diabetes: establishing a new pathway to secondary prevention of cardiovascular disease PubMed pubmed.ncbi.nlm.nih.gov [3] Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial PubMed pubmed.ncbi.nlm.nih.gov [4] Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial PubMed pubmed.ncbi.nlm.nih.gov [5] GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)
Niraj Choudhary, MD, and Dr
Post-treatment weight regain following discontinuation of GLP-1 receptor agonist therapy
The goal is to provide a temporary pathway for eligible patients while broader questions about Medicare coverage of weight-loss medications continue
c , Homeostatic model assessment of insulin resistance (HOMA-IR) (n = 7 Vhcl, n = 6 GLP-1:Lani, n = 8 GLP-1:GIP:Lani)
What are your thoughts on those applications, and is this something where we need to rethink our relationship with medicine, or do you think there are risks
